Ratings SIGA Technologies, Inc.

Equities

SIGA

US8269171067

Real-time Estimate Cboe BZX Other stock markets 01:06:56 2024-04-23 pm EDT			5-day change	1st Jan Change
8.745 ^USD	+4.73%		-1.79%	+56.61%

Apr. 01	SIGA Technologies to Drive International Promotion for Oral TPOXX in Amended Deal With Meridian Medical	MT
Apr. 01	SIGA Technologies, Inc. Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX	CI

Summary

The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.

Weaknesses

The company's earnings growth outlook lacks momentum and is a weakness.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
SIGA TECHNOLOGIES, INC.	+56.61%	594M	C-
ELI LILLY AND COMPANY	+27.33%	659B	C+
NOVO NORDISK A/S	+27.68%	557B	B
JOHNSON & JOHNSON	-4.13%	359B	C+
MERCK & CO., INC.	+16.66%	322B	B-
ABBVIE INC.	+9.79%	297B	C+
ASTRAZENECA PLC	+6.30%	215B	B+
NOVARTIS AG	+4.80%	210B	B-
ROCHE HOLDING AG	-6.05%	200B	A+
PFIZER, INC.	-8.81%	149B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes